查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1462610

放射治疗口腔黏膜炎的全球市场：分析 - 按治疗类型、放射治疗类型、口腔黏膜炎严重程度、最终使用者、地区和预测（截至 2030 年）

Radiotherapy Induced Oral Mucositis Treatment Market Forecasts to 2030 - Global Analysis By Treatment Type (Topical Agents, Systemic Agents and Medical Devices), Radiotherapy Type, Severity of Oral Mucositis, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

预计2023年全球放射治疗口腔黏膜炎治疗市场规模将达51.5亿美元，预测期内复合年增长率为5.4%，2030年将达74.4亿美元。

口腔黏膜炎的放射治疗 (RIOM) 治疗通常涉及多方面的方法，旨在控制症状并促进癒合。这包括口腔卫生措施，例如轻轻刷牙、生理食盐水和处方漱口水，以减少微生物生长并缓解疼痛。使用放射疗法治疗口腔黏膜炎在改善患者预后和提高癌症治疗的耐受性方面发挥重要作用。

根据世界卫生组织 (WHO) 的数据，癌症是世界第二大死因，2018 年估计有 960 万人死亡，美国每年有超过 40 万人被诊断出患有口腔黏膜炎。

老年人口不断增加

随着老龄化，我们变得更容易受到放射治疗引起的口腔併发症，从而增加了对有针对性的解决方案的需求。 RIOM 可以对接受癌症治疗的老年患者的生活品质产生重大影响。随着这一人群的持续增长，迫切需要创新的治疗方法来缓解疼痛、进食和说话困难等 RIOM 症状，并且迫切需要针对老年患者的需求进行治疗方法的进展，其重要性已得到强调和重视。市场成长。

认识有限

对 RIOM 管理和预防的认识有限可能会阻碍有效的治疗。患者可能无法识别早期症状或了解预防措施的重要性，从而导致干预延迟和症状恶化。如果没有适当的教育和认识，患者可能无法坚持规定的治疗和生活方式的改变，从而使 RIOM 的管理更加复杂并影响治疗结果。

医疗保健支出增加

由于 RIOM 治疗在接受放射治疗的癌症患者中普遍存在，医疗保健支出的增加正在推动对 RIOM 治疗等有效治疗的需求。随着医疗保健预算的扩大，对创新治疗方法解决 RIOM 的衰弱影响，例如疼痛和饮食困难。资金的增加将鼓励新治疗方法的研究。因此，医疗保健提供者将更有可能采用这些解决方案，从而加强 RIOM 治疗选择的市场，并促进肿瘤学环境中患者照护的进一步进步。

医疗基础设施不足

医疗基础设施不足给 RIOM 的有效治疗带来了重大挑战。专业医疗机构和训练有素的人员的使用机会有限可能会延迟诊断和介入。资源缺乏可能导致用于治疗 RIOM 症状的基本药物和设备短缺，例如止痛药和口腔卫生产品。此外，基础设施不足可能会阻碍患者教育和后续护理，从而降低治疗结果的整体品质。

COVID-19 的影响

COVID-19 的爆发对 RIOM 治疗市场产生了重大影响。癌症诊断和治疗的延误以及医疗保健服务的中断导致患者数量减少和手术推迟，影响了对 RIOM 治疗的需求。此外，严格的感染控制措施和医疗机构内的资源重新分配进一步阻碍了市场成长。然而，远距远端医疗和居家照护解决方案的进步已成为缓解这些挑战的潜在策略，即使在疫情期间也有助于继续获得 RIOM 治疗方案。

近距离放射治疗产业预计将在预测期内成为最大的产业

近距离放射治疗领域预计将出现良好的成长。近距离放射治疗是放射治疗的一种型态，正在成为治疗放射治疗引起的口腔黏膜炎的一种有前途的治疗方法。近距离放射治疗直接向受影响区域提供定向辐射，最大限度地减少对周围健康组织的损害。结果显示有可能减轻 RIOM 症状的严重程度并改善患者的生活品质。其功效和精确度使其成为不断发展的 RIOM治疗方法领域的重要候选者。

预计癌症治疗中心领域在预测期内的复合年增长率最高。

预计癌症治疗中心产业在预测期内的复合年增长率最高。在癌症治疗中心使用放射疗法治疗口腔黏膜炎通常涉及多方面的方法，旨在控制疼痛、预防感染和促进癒合。此外，可以采用低强度雷射疗法和冷冻疗法等先进技术来减少发炎并促进组织修復。目的是在癌症治疗期间缓解症状、保持口腔卫生并改善患者的生活品质。

比最大的地区

由于癌症发病率上升和放射治疗技术的进步，预计亚太地区在预测期内将占据最大的市场占有率。此外，政府的支持措施和医疗基础设施的改善正在促进市场开拓。主要企业注重策略联盟和产品创新，以获得竞争优势。总体而言，亚太地区放射治疗口腔黏膜炎治疗市场预计在可预见的未来将继续成长。

复合年增长率最高的地区：

由于癌症发生率高、医疗基础设施先进和技术进步，预计欧洲在预测期内的复合年增长率最高。该地区正在对创新放射治疗技术进行大量投资。此外，有利的报销政策和主要市场参与者的强大影响力也促进了市场的成长。人们对放射治疗作为各种癌症治疗选择的有效性的认识不断提高，进一步推动了需求。

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二次研究资讯来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • COVID-19 的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球放射治疗口腔黏膜炎治疗市场：依治疗类型

  • 外用製剂
    • 止痛药
    • 抗菌漱口水
    • 麻醉剂
    • 被覆剂
  • 全身性药物
    • 疼痛管理药物
    • 生长促进因子
  • 医疗设备
    • 低强度雷射治疗 (LLLT)
    • 口腔冷冻治疗仪

第六章全球放射治疗口腔黏膜炎治疗市场：依放射治疗类型

  • 外部放射治疗（EBRT）
  • 强度调控放射治疗(IMRT)
  • 近距离放射治疗
  • 质子治疗
  • 立体定位放射线手术(SRS)
  • 其他放射治疗类型

第七章全球口腔黏膜炎放射治疗市场：依口腔黏膜炎的严重程度分类

  • 温和的
  • 缓和
  • 严重
  • 危害生命

第八章全球放射治疗口腔黏膜炎治疗市场：依最终使用者分类

  • 医院
  • 癌症治疗中心
  • 门诊手术中心
  • 调查机构
  • 其他最终用户

第九章全球放射治疗口腔黏膜炎治疗市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东/非洲

第10章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司概况

  • The 3M Company
  • GlaxoSmithKline PLC
  • Sun Pharmaceutical Industries Limited
  • Fagron Group BV
  • Pfizer Inc.
  • Merck & Co. Inc.
  • Eusa Pharma
  • Valeant Pharmaceuticals International Inc.
  • Eisai Corporation
  • Amgen Inc.
  • Galera Therapeutics Inc.
  • EpicentRx
  • Soligenix Inc.
  • Cellceutix Corporation
  • GI Solutions Group
Product Code: SMRC25661

According to Stratistics MRC, the Global Radiotherapy Induced Oral Mucositis Treatment Market is accounted for $5.15 billion in 2023 and is expected to reach $7.44 billion by 2030 growing at a CAGR of 5.4% during the forecast period. Radiotherapy-induced oral mucositis (RIOM) treatment typically involves a multifaceted approach aimed at managing symptoms and promoting healing. These may include oral hygiene measures like gentle brushing and rinsing with saline solution or prescribed mouthwashes to reduce microbial growth and alleviate pain. Radiotherapy-induced oral mucositis treatment plays a crucial role in improving patient outcomes and enhancing the tolerability of cancer therapy.

According to the World Health Organization (WHO), cancer is the second leading cause of death globally, with an estimated 9.6 million deaths in 2018 and over 400,000 people in the US are estimated to receive an oral mucositis diagnosis each year.

Market Dynamics:

Driver:

Expanding geriatric population

With age, individuals become more susceptible to oral complications from radiotherapy, exacerbating the need for targeted solutions. RIOM can significantly impact the quality of life for elderly patients undergoing cancer treatment. As this demographic continues to grow, there is a pressing need for innovative therapies that alleviate RIOM symptoms, such as pain and difficulty in eating and speaking, thus highlighting the importance of advancing treatments tailored to meet the needs of older patients, thereby, driving the market growth.

Restraint:

Limited awareness

Limited awareness about the management and prevention of RIOM can hinder effective treatment. Patients may not recognize early symptoms or understand the importance of preventive measures, leading to delayed intervention and exacerbation of symptoms. Without proper education and awareness, patients may not adhere to prescribed treatments or lifestyle modifications, further complicating the management of RIOM and potentially compromising treatment outcomes.

Opportunity:

Rising healthcare expenditure

Rising healthcare expenditure drives demand for effective treatments like RIOM treatment due to its prevalence in cancer patients undergoing radiation therapy. With healthcare budgets expanding, there's greater investment in innovative therapies addressing RIOM's debilitating effects, such as pain and difficulty eating. This increased funding facilitates research into novel treatment modalities. Consequently, healthcare providers are more inclined to adopt these solutions, bolstering the market for RIOM treatment options and driving further advancements in patient care within oncology settings.

Threat:

Inadequate healthcare infrastructure

Inadequate healthcare infrastructure poses significant challenges to effective treatment of RIOM. Limited access to specialized healthcare facilities and trained personnel can delay diagnosis and intervention. Insufficient resources may lead to shortages of essential medications and equipment necessary for managing RIOM symptoms, such as pain relievers and oral hygiene products. Additionally, inadequate infrastructure may hinder patient education and follow-up care, reducing the overall quality of treatment outcomes.

Covid-19 Impact

The covid-19 pandemic has significantly impacted the RIOM treatment market. Delays in cancer diagnoses and treatments, along with disruptions in healthcare services, have led to reduced patient volumes and procedural postponements, affecting the demand for RIOM treatments. Additionally, stringent infection control measures and resource reallocations within healthcare facilities have further impeded market growth. However, advancements in telemedicine and homecare solutions have emerged as potential strategies to mitigate these challenges, facilitating continued access to RIOM treatment options amidst the pandemic.

The brachytherapy segment is expected to be the largest during the forecast period

The brachytherapy segment is estimated to have a lucrative growth. Brachytherapy, a form of radiotherapy, is emerging as a promising treatment for radiotherapy induced oral mucositis. Brachytherapy delivers targeted radiation directly to the affected area, minimizing damage to surrounding healthy tissue. As a result, it shows potential in reducing the severity of RIOM symptoms and improving patient quality of life. Its efficacy and precision make it a significant contender in the evolving landscape of RIOM treatment modalities.

The cancer treatment centers segment is expected to have the highest CAGR during the forecast period

The cancer treatment centers segment is anticipated to witness the highest CAGR growth during the forecast period. Radiotherapy-induced oral mucositis treatment in cancer treatment centers typically involves a multifaceted approach aimed at managing pain, preventing infection, and promoting healing. Additionally, advanced techniques like low-level laser therapy or cryotherapy may be employed to reduce inflammation and promote tissue repair. The goal is to mitigate symptoms, maintain oral hygiene, and improve the patient's quality of life during cancer treatment.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to rising cancer incidence and advancements in radiotherapy techniques. Moreover, supportive government initiatives and improving healthcare infrastructure are fostering market development. Key players are focusing on strategic collaborations and product innovations to gain a competitive edge. Overall, the Asia Pacific radiotherapy induced oral mucositis treatment market is poised for continuous growth in the foreseeable future.

Region with highest CAGR:

Europe is projected to have the highest CAGR over the forecast period, owing to high prevalence of cancer, advanced healthcare infrastructure, and technological advancements. The market sees significant investments in innovative radiotherapy technologies in the region. Moreover, favourable reimbursement policies and a strong presence of key market players contribute to market growth. Increasing awareness about the efficacy of radiotherapy as a treatment option for various cancers, further fuels demand.

Key players in the market

Some of the key players profiled in the Radiotherapy Induced Oral Mucositis Treatment Market include The 3M Company, GlaxoSmithKline PLC, Sun Pharmaceutical Industries Limited, Fagron Group BV, Pfizer Inc., Merck & Co. Inc., Eusa Pharma, Valeant Pharmaceuticals International Inc., Eisai Corporation, Amgen Inc., Galera Therapeutics Inc., EpicentRx, Soligenix Inc., Cellceutix Corporation and GI Solutions Group.

Key Developments:

In March 2023, EpicentRx announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to RRx-001, a direct NLRP3 inhibitor and Nrf2 upregulator with anti-inflammatory and antioxidant properties, for the prevention/attenuation of severe oral mucositis in chemotherapy and radiation-treated head & neck cancer patients.

In February 2023, Galera Therapeutics announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and granted priority review to the New Drug Application (NDA) for avasopasem manganese for radiotherapy (RT)-induced severe oral mucositis (SOM) in patients with head and neck cancer (HNC) undergoing standard-of-care treatment.

Treatment Types Covered:

  • Topical Agents
  • Systemic Agents
  • Medical Devices

Radiotherapy Types Covered:

  • External Beam Radiation Therapy (EBRT)
  • Intensity-Modulated Radiation Therapy (IMRT)
  • Brachytherapy
  • Proton Therapy
  • Stereotactic Radiosurgery (SRS)
  • Other Radiotherapy Types

Severity of Oral Mucositis Covered:

  • Mild
  • Moderate
  • Severe
  • Life-threatening

End Users Covered:

  • Hospitals
  • Cancer Treatment Centers
  • Ambulatory Surgical Centers
  • Research Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Radiotherapy Induced Oral Mucositis Treatment Market, By Treatment Type

  • 5.1 Introduction
  • 5.2 Topical Agents
    • 5.2.1 Analgesics
    • 5.2.2 Antimicrobial Mouthwash
    • 5.2.3 Anesthetics
    • 5.2.4 Coating Agents
  • 5.3 Systemic Agents
    • 5.3.1 Pain Management Drugs
    • 5.3.2 Growth Factors
  • 5.4 Medical Devices
    • 5.4.1 Low-Level Laser Therapy (LLLT)
    • 5.4.2 Oral Cryotherapy Devices

6 Global Radiotherapy Induced Oral Mucositis Treatment Market, By Radiotherapy Type

  • 6.1 Introduction
  • 6.2 External Beam Radiation Therapy (EBRT)
  • 6.3 Intensity-Modulated Radiation Therapy (IMRT)
  • 6.4 Brachytherapy
  • 6.5 Proton Therapy
  • 6.6 Stereotactic Radiosurgery (SRS)
  • 6.7 Other Radiotherapy Types

7 Global Radiotherapy Induced Oral Mucositis Treatment Market, By Severity of Oral Mucositis

  • 7.1 Introduction
  • 7.2 Mild
  • 7.3 Moderate
  • 7.4 Severe
  • 7.5 Life-threatening

8 Global Radiotherapy Induced Oral Mucositis Treatment Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals
  • 8.3 Cancer Treatment Centers
  • 8.4 Ambulatory Surgical Centers
  • 8.5 Research Institutes
  • 8.6 Other End Users

9 Global Radiotherapy Induced Oral Mucositis Treatment Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 The 3M Company
  • 11.2 GlaxoSmithKline PLC
  • 11.3 Sun Pharmaceutical Industries Limited
  • 11.4 Fagron Group BV
  • 11.5 Pfizer Inc.
  • 11.6 Merck & Co. Inc.
  • 11.7 Eusa Pharma
  • 11.8 Valeant Pharmaceuticals International Inc.
  • 11.9 Eisai Corporation
  • 11.10 Amgen Inc.
  • 11.11 Galera Therapeutics Inc.
  • 11.12 EpicentRx
  • 11.13 Soligenix Inc.
  • 11.14 Cellceutix Corporation
  • 11.15 GI Solutions Group

List of Tables

  • Table 1 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Treatment Type (2021-2030) ($MN)
  • Table 3 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Topical Agents (2021-2030) ($MN)
  • Table 4 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Analgesics (2021-2030) ($MN)
  • Table 5 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Antimicrobial Mouthwash (2021-2030) ($MN)
  • Table 6 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Anesthetics (2021-2030) ($MN)
  • Table 7 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Coating Agents (2021-2030) ($MN)
  • Table 8 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Systemic Agents (2021-2030) ($MN)
  • Table 9 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Pain Management Drugs (2021-2030) ($MN)
  • Table 10 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Growth Factors (2021-2030) ($MN)
  • Table 11 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Medical Devices (2021-2030) ($MN)
  • Table 12 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Low-Level Laser Therapy (LLLT) (2021-2030) ($MN)
  • Table 13 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Oral Cryotherapy Devices (2021-2030) ($MN)
  • Table 14 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Radiotherapy Type (2021-2030) ($MN)
  • Table 15 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By External Beam Radiation Therapy (EBRT) (2021-2030) ($MN)
  • Table 16 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Intensity-Modulated Radiation Therapy (IMRT) (2021-2030) ($MN)
  • Table 17 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Brachytherapy (2021-2030) ($MN)
  • Table 18 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Proton Therapy (2021-2030) ($MN)
  • Table 19 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Stereotactic Radiosurgery (SRS) (2021-2030) ($MN)
  • Table 20 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Other Radiotherapy Types (2021-2030) ($MN)
  • Table 21 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Severity of Oral Mucositis (2021-2030) ($MN)
  • Table 22 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Mild (2021-2030) ($MN)
  • Table 23 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Moderate (2021-2030) ($MN)
  • Table 24 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Severe (2021-2030) ($MN)
  • Table 25 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Life-threatening (2021-2030) ($MN)
  • Table 26 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 27 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 28 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Cancer Treatment Centers (2021-2030) ($MN)
  • Table 29 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 30 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Research Institutes (2021-2030) ($MN)
  • Table 31 Global Radiotherapy Induced Oral Mucositis Treatment Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.